Date published: 2026-5-19

1-800-457-3801

SCBT Portrait Logo
Seach Input

SDZ WAG 994 (CAS 130714-47-5)

0.0(0)
Write a reviewAsk a question

Alternate Names:
N-Cyclohexyl-2′-O-methyladenosine
Application:
SDZ WAG 994 is a selective Adenosine A1-R agonist
CAS Number:
130714-47-5
Molecular Weight:
363.41
Molecular Formula:
C17H25N5O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

SDZ WAG 994 is a selective and potent and A1 adenosine receptor agonist (Ki values are 23, > 10000 and 25000 nM for A1, A2A and A2B receptors respectively).


SDZ WAG 994 (CAS 130714-47-5) References

  1. Lipoic acid acutely induces hypoglycemia in fasting nondiabetic and diabetic rats.  |  Khamaisi, M., et al. 1999. Metabolism. 48: 504-10. PMID: 10206446
  2. N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.  |  Knutsen, LJ., et al. 1999. J Med Chem. 42: 3463-77. PMID: 10479279
  3. A1 adenosine receptor: role in diabetes and obesity.  |  Dhalla, AK., et al. 2009. Handb Exp Pharmacol. 271-95. PMID: 19639285
  4. A Fall in plasma free fatty acid (FFA) level activates the hypothalamic-pituitary-adrenal axis independent of plasma glucose: evidence for brain sensing of circulating FFA.  |  Oh, YT., et al. 2012. Endocrinology. 153: 3587-92. PMID: 22669895
  5. Counter-regulatory response to a fall in circulating fatty acid levels in rainbow trout. Possible involvement of the hypothalamus-pituitary-interrenal axis.  |  Librán-Pérez, M., et al. 2014. PLoS One. 9: e113291. PMID: 25405879
  6. Metabolic response in liver and Brockmann bodies of rainbow trout to inhibition of lipolysis; possible involvement of the hypothalamus-pituitary-interrenal (HPI) axis.  |  Librán-Pérez, M., et al. 2015. J Comp Physiol B. 185: 413-23. PMID: 25666862
  7. 4-amino-6-alkyloxy-2-alkylthiopyrimidine derivatives as novel non-nucleoside agonists for the adenosine A1 receptor.  |  Cosimelli, B., et al. 2016. Chem Biol Drug Des. 88: 724-729. PMID: 27282729
  8. Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives.  |  Deb, PK., et al. 2019. Curr Pharm Des. 25: 2697-2715. PMID: 31333094
  9. The adenosine A1 receptor agonist WAG 994 suppresses acute kainic acid-induced status epilepticus in vivo.  |  Klaft, ZJ., et al. 2020. Neuropharmacology. 176: 108213. PMID: 32615188
  10. Purinergic signaling in peripheral nervous system glial cells.  |  Patritti-Cram, J., et al. 2021. Glia. 69: 1837-1851. PMID: 33507559
  11. The cardiac effects of a novel A1-adenosine receptor agonist in guinea pig isolated heart.  |  Belardinelli, L., et al. 1994. J Pharmacol Exp Ther. 271: 1371-82. PMID: 7996449
  12. Rationale and hurdles of inhibitors of hepatic gluconeogenesis in treatment of diabetes mellitus.  |  Kashiwagi, A. 1995. Diabetes Res Clin Pract. 28 Suppl: S195-200. PMID: 8529514
  13. A tandem solid phase extraction, reversed-phase HPLC method for determining SDZ WAG 994 in dog, monkey and rat blood.  |  Cramer, JA., et al. 1997. J Pharm Biomed Anal. 15: 749-58. PMID: 9172100
  14. Hypoglycemic and hypotensive effects of 6-cyclohexyl-2'-O-methyl-adenosine, an adenosine A1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia.  |  Ishikawa, J., et al. 1998. Diabetes Res Clin Pract. 39: 3-9. PMID: 9597368

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

SDZ WAG 994, 10 mg

sc-204275
10 mg
$169.00